News | March 04, 2024
Govt. setting up of Ayush - ICMR Advanced Centre for AI-ACIHR at select AIIMS
Launch of Indian public health standards for Ayush healthcare facilities
Launch of Indian public health standards for Ayush healthcare facilities
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
_in_Mizushima,_Japan_256_384.jpg)
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
We are achieving the target of developed India by making our young children healthy today
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Subscribe To Our Newsletter & Stay Updated
